Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells

Cancer Biology and Therapy

Volumn 4, Issue 7, 2005, Pages 716-719

  Wang, Zehua ^a   Xie, Yanhua ^a   Wang, Hongbo ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Apoptosis; Mdr1; Ovarian cancer; Platinum; RT PCR; Survivin; Taxol

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; MESSENGER RNA; PACLITAXEL; PLATINUM DERIVATIVE; SURVIVIN; TAXANE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; COMPARATIVE STUDY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; OVARY CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 25144459002     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.7.1782     Document Type: Article

References (27)

1. Kalil NG, McGuire WP. Chemotherapy for advanced epithelial ovarian carcinoma. Best Pract Res Clin Obstet Gynaecol 2002; 16:553-71.
2. Christian MC, Trimble EL. Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol Oncol 1994; 55:5143-50.
3. Perez RP, Hamilton TC, Ozols RF, Young RC. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer 1993; 71:1571-80.
4. Poulain L, Lincet H, Duigou F, Deslandes E, Sichel F, Gauduchon P, Staedel C. Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control. Int J Cancer 1998; 78:454-63.
5. Wu GS, Ding Z. Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line. Oncogene 2002; 21:1-8.
6. Flick MB, O'Malley D, Rutherford T, Rodov S, Kamsteeg M, Hao XY, Schwartz P, Kacinski BM, Mor G. Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients. J Soc Gynecol Investig 2004; 11:252-9.
7. Rogers PM, Beale PJ, Al-Moundhri M, Boxall F, Patterson L, Valenti M, Raynaud F, Hobbs S, Johnston S, Kelland LR. Overexpression of BclXL in a human ovarian carcinoma cell line: Paradoxic effects on chemosensitivity in vitro versus in vivo. Int J Cancer 2002; 97:858-63.
8. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3:917-21.
9. Altieri DC. Molecular circuits of apoptosis regulation and cell division control: The survivin paradigm. J Cell Biochem 2004; 92:656-63.
10. Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino F, Daidone MG. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002; 59:1406-12.
11. Ikeguchi M, Liu J, Kaibara N. Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment. Apoptosis 2002; 7:23-9.
12. Schondorf T, Kurbacher CM, Gohring UJ, Benz C, Becker M, Sartorius J, Kolhagen H, Mailman P, Neumann R. Induction of MDR1-gene expression by antineoplastic agents in ovarian cancer cell lines. Anticancer Res 2002; 22:2199-203.
13. Li L, Luan Y, Li X, Tang B, Zhang W, Li D, Zhao J, Wang G, Ding H, Reed E, Li QQ. Demonstration of differential gene expression between sensitive and resistant ovarian tumor cells by fluorescence differential display-PCR analysis. Oncol Rep 2005; 13:793-9.
14. Kurdi M, Randon J, Cerutti C, Bricca G. Increased expression of IL-6 and LIF in the hypertrophied left ventricle of TGR(mRen2)27 and SHR rats. Mol Cell Biochem 2005; 269:95-101.
15. Pesce CD, Bolacchi F, Bongiovanni B, Cisotta F, Capozzi M, Diviacco S, Quadrifoglio F, Mango R, Novelli G, Mossa G, Esposito C, Ombres D, Rocchi G, Bergamini A. Anti-gene peptide nucleic acid targeted to proviral HIV-1 DNA inhibits in vitro HIV-1 replication. Antiviral Res 2005; 66:13-22.
16. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52:23-47.
17. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1-6.
18. Coukos G, Rubin SC. Chemotherapy resistance in ovarian cancer: New molecular perspectives. Obstet Gynecol 1998; 91:783-792.
19. Gadducci A, Cosio S, Muraca S, Genazzani AR. Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: Biological data and clinical implications. Eur J Gynaecol Oncol 2002; 23:390-396.
20. Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, Hu YY, Liu JR. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 2005; 96:287-95.
21. Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK, Oh BH. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001; 40:1117-23.
22. Li F, Altieri DC. The cancer antiapoptosis mouse survivin gene: Characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res 1999; 59:3143-51.
23. O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, Tognin S, Marchisio PC, Altieri DC. Regulation of apoptosis at cell division by p34cdc.2 phosphorylation of survivin. Proc Natl Acad Sci USA 2000; 97:13103-7.
24. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: From genomics to mechanism. Oncogene 2003; 22:7468-85.
25. Nooter K, Herweijer H. Multidrug resistance (mdr) genes in human cancer. Br J Cancer 1991; 63:663-9.
26. Komuro Y, Watanabe T, Tsurita G, Muto T, Nagawa H. Survivin expression in ovarian carcinoma: Correlation with apoptotic markers and prognosis. Mod Pathol 2004; 17:264.
27. Ferrandina G, Legge F, Martinelli E, Ranelletti FO, Zannoni GF, Lauriola L, Gessi M, Gallotta V, Scambia G. Survivin expression in ovarian cancer and its correlation with clinicopathological, surgical and apoptosis-related parameters. Br J Cancer 2005; 92:271-7.